JP2009543860A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543860A5
JP2009543860A5 JP2009520710A JP2009520710A JP2009543860A5 JP 2009543860 A5 JP2009543860 A5 JP 2009543860A5 JP 2009520710 A JP2009520710 A JP 2009520710A JP 2009520710 A JP2009520710 A JP 2009520710A JP 2009543860 A5 JP2009543860 A5 JP 2009543860A5
Authority
JP
Japan
Prior art keywords
chloro
formula
compound
benzofuran
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009520710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543860A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2007/000694 external-priority patent/WO2008010765A1/en
Publication of JP2009543860A publication Critical patent/JP2009543860A/ja
Publication of JP2009543860A5 publication Critical patent/JP2009543860A5/ja
Pending legal-status Critical Current

Links

JP2009520710A 2006-07-19 2007-07-17 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 Pending JP2009543860A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83177606P 2006-07-19 2006-07-19
PCT/SE2007/000694 WO2008010765A1 (en) 2006-07-19 2007-07-17 Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
JP2009543860A JP2009543860A (ja) 2009-12-10
JP2009543860A5 true JP2009543860A5 (enExample) 2010-08-26

Family

ID=38957025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520710A Pending JP2009543860A (ja) 2006-07-19 2007-07-17 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用

Country Status (17)

Country Link
US (2) US20080167332A1 (enExample)
EP (1) EP2069355A4 (enExample)
JP (1) JP2009543860A (enExample)
KR (1) KR20090030347A (enExample)
CN (1) CN101553493B (enExample)
AR (2) AR061923A1 (enExample)
AU (1) AU2007275931B2 (enExample)
BR (1) BRPI0714463A2 (enExample)
CA (1) CA2657639A1 (enExample)
CL (2) CL2007002099A1 (enExample)
IL (1) IL196323A0 (enExample)
MX (1) MX2009000475A (enExample)
NO (1) NO20090760L (enExample)
PE (1) PE20090626A1 (enExample)
TW (2) TW200821316A (enExample)
UY (1) UY30493A1 (enExample)
WO (1) WO2008010765A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
KR20090030347A (ko) * 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
EP2120935A4 (en) * 2007-02-23 2011-06-22 Astrazeneca Ab NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2008103125A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
NZ586106A (en) 2007-12-20 2012-09-28 Astrazeneca Ab Device, typically for medicament powder, for deaggregating powder by passing air stream along flat region with recess of brick shape where eddy is generated
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2010007408A2 (en) * 2008-07-14 2010-01-21 Astrazeneca Ab Intermediates 2-(2-chloro-5-hydroxy-4-methylcarbamoylphenoxy)-2-methylpropionic acid tert-butyl ester and glycidyl benzene sulfonates or salts thereof and the process for preparation of said intermediates
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2341967A4 (en) 2008-10-08 2016-03-09 Astrazeneca Ab INHALER WITH INDEXATION BASED ON MOVEMENT OF COVERAGE
ES2579902T3 (es) 2008-10-08 2016-08-17 Astrazeneca Ab Dispositivo de inhalación para administrar un medicamento
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2440563A1 (en) * 2009-06-10 2012-04-18 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2448623B1 (en) 2009-07-01 2017-12-20 AstraZeneca AB Dispenser and method for entraining powder in an airflow
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
MX2012008906A (es) 2010-02-10 2012-08-15 Astrazeneca Uk Ltd Proceso para proporcionar un cartucho relleno para un inhalador.
JP5850932B2 (ja) 2010-07-21 2016-02-03 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag 吸入器
CN103118727B (zh) 2010-07-21 2015-11-25 阿斯利康(瑞典)有限公司 吸入器
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
GB201115870D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
EP3730590A1 (de) * 2014-03-10 2020-10-28 Merck Patent GmbH Flüssigkristalline medien mit homöotroper ausrichtung
NL2019273B1 (nl) 2017-07-19 2019-02-25 Synbra Tech B V houder voor vloeistoffen
CN111170753B (zh) * 2020-01-21 2022-05-17 烟台大学 一种具有耐高温性能的含电路屏陶瓷吸波材料及其制备方法
CN116640062B (zh) * 2023-05-23 2025-07-01 贵州中医药大学 一种新型坝巴酸醚类衍生物及其合成方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) * 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4263317A (en) * 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
DE3822449A1 (de) * 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216339A1 (de) 2002-04-13 2003-10-23 Boehringer Ingelheim Pharma Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
ATE555087T1 (de) * 2002-11-27 2012-05-15 Incyte Corp 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302755D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) * 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) * 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
KR20090030347A (ko) * 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
WO2008103125A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
EP2120935A4 (en) * 2007-02-23 2011-06-22 Astrazeneca Ab NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA

Similar Documents

Publication Publication Date Title
JP2009543860A5 (enExample)
JP2006143751A5 (enExample)
JP2009536191A5 (enExample)
JP2013510883A5 (enExample)
JP2008501705A5 (enExample)
JP2016534063A5 (enExample)
WO2008104776A1 (en) Combinations of beta-2-adrenoceptor agonistic benzothiazolone
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2012085582A1 (en) Compound
JP2020502206A (ja) Task−1およびtask−3チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
TWI757726B (zh) 4(1h)-奎諾酮衍生物及其用途
JP2008534453A5 (enExample)
JP2020502215A (ja) Task−1およびtask−3チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
RU2008124833A (ru) Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций
WO2012085583A1 (en) New compound
JP2011046708A5 (enExample)
JP2005532397A5 (enExample)
JP2005513017A5 (enExample)
JP2014511897A5 (enExample)
US20110124613A1 (en) Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
CN113194924B (zh) 制备包含task-1和task-3通道抑制剂的药物剂型的方法及其在呼吸障碍治疗中的用途
JP2013523739A5 (enExample)
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
US20120202860A2 (en) Analgesic Compounds, Compositions and Uses Thereof
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3